CFRDにおけるバイオニック膵臓
嚢胞性線維症関連糖尿病におけるインスリンのみの生体膵臓のランダム化試験
This multi-center randomized controlled trial (RCT) will compare efficacy and safety endpoints using the insulin-only configuration of the iLet Bionic Pancreas System (BP) versus a control group using their usual care insulin delivery method and continuous glucose monitoring (CGM) during a 13-week study period in individuals ≥14 years old with cystic fibrosis-related diabetes (CFRD). After 13 weeks, participants will continue in a 13-week Extension Phase in which the BP group will continue to use the BP system and the Usual Care group will initiate use of the BP system.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- University of Colorado-Barbara Davis Center for Diabetes
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06511
- Yale University School of Medicine
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30329
- Emory University
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46202
- Indiana University School of Medicine
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- Johns Hopkins University School of Medicine
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- Massachusetts General Hospital
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55455
- University of Minnesota
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64108
- Children's Mercy Hospital
-
-
New York
-
New York、New York、アメリカ、10032
- Columbia University Medical Center
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106
- University Hospitals of Cleveland
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- Children's Hospital of Philadelphia
-
-
Texas
-
Dallas、Texas、アメリカ、75235
- UT Southwestern Medical Center
-
Houston、Texas、アメリカ、77030
- Baylor College of Medicine
-
San Antonio、Texas、アメリカ、78207
- University of Texas Health San Antonio
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84132
- University of Utah
-
-
Virginia
-
Charlottesville、Virginia、アメリカ、22903
- University of Virginia-Center for Diabetes Technology
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion
-
Age ≥ 14 years old at time of signing informed consent
-
Able to provide informed consent (and assent for participants <18 years old)
-
Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria:
- Sweat chloride equal to or greater than 60 mmol/liter by quantitative pilocarpine iontophoresis test (QPIT) (when not taking a cystic fibrosis transmembrane conductance regulator (CFTR) modulator)
- Two well-characterized mutations in the CFTR gene
-
Clinical diagnosis of CFRD, defined as a person with CF and diabetes mellitus, treated with insulin for ≥3 months prior to screening
-
Using the same insulin regimen for ≥1 month prior to screening and collection of baseline CGM data, with no plans to change regimen during the study: either multiple daily injections of insulin (MDI), basal-only without bolus insulin, an insulin pump without automation, or an automated insulin delivery (AID) system other than the BP (which is an exclusion)
-
Total daily insulin dose must be ≥0.1 units/kg
-
Able to speak and read English sufficient to understand the pump user interface and provide written materials for safe operation of the BP
• For pediatric participants, this applies to both the participant and caregiver
-
For participants <18 years old, living with one or more parent/legal guardian knowledgeable about emergency procedures for severe hypoglycemia. A designated care partner must be willing to be linked to the participant's Dexcom Follow application with location sharing on.
-
For participants >18 years old who live alone, participant has a relative or acquaintance who lives within 30 minutes of participant and is willing to be contacted to check on participant if study staff feel that participant may be experiencing a medical emergency and cannot be reached. A designated care partner must be willing to be linked to the participant's Dexcom Follow application with location sharing on.
-
No use of a non-insulin glucose-lowering medication, except metformin, that is not approved for use in T1D within 3 months prior to signing informed consent and willing to not use any such medications during the course of the trial. Note: such drugs cannot be used even if prescribed for weight loss rather than glucose-lowering.
-
If not currently using a rapid-acting insulin that is approved for use in the iLet pump, willing and able to switch to an approved insulin when using the BP.
-
Participant has commercial glucagon available for treatment of severe hypoglycemia or will obtain it prior to randomization
-
Willing to authorize the study team to contact the participant's primary physician to inform them about their participation in this study.
-
Enrolled in the Cystic Fibrosis Foundation Patient Registry (participants may enroll in the Registry at the time of enrollment if not already enrolled).
-
No plans for trips of more than 14 consecutive days outside the United States during the period of study participation
-
Investigator believes that the participant can safely use the iLet and will follow the protocol • The investigator will take into account the participant's HbA1c level (there is no upper limit for eligibility), compliance with current diabetes management, prior acute diabetic complications, cognitive ability, and general medical condition. For this reason, there is no upper limit on HbA1c specified for eligibility.
Exclusion
-
Current use of the BP or an AID system not FDA approved for T1D
-
Known hemoglobinopathy (sickle cell trait is not an exclusion)
-
Current participation in another diabetes-related interventional trial
-
Established history of allergy or severe reaction to adhesive or tape that must be used in the study
-
Pregnant (positive urine hCG), breast feeding, plan to become pregnant in the next 7 months, or sexually active and can become pregnant but not using contraception
-
Current use of hydroxyurea or unable to avoid hydroxyurea use during the study (interferes with accuracy of Dexcom sensor)
-
Have started or stopped a CFTR modulator in the 4 weeks prior to screening.
• Modifications of the dosing of a CFTR modulator is acceptable
-
Anticipated lung or liver transplant (on transplant list)
-
Lung or liver transplant within one year prior to screening. If they have had a transplant more than a year ago, but they:
- Have had a rejection episode occur in prior 8 weeks, individual is excluded.
- Their doses of corticosteroids and/or calcineurin inhibitors have not been stable for one month prior to enrollment and/or is expected to change significantly over the course of the study, individual is excluded.
-
Acute pulmonary exacerbation or hospitalization within the 4 weeks prior to screening or treatment with IV antibiotics in the 4 weeks prior to screening
-
History of a complete pancreatectomy
-
Currently using enteral tube feedings for nutritional support
-
Presence of a medical condition or use of a medication that, in the judgment of the investigator, clinical protocol chair, or medical monitor, could compromise the results of the study or the safety of the participant. Conditions to be considered by the investigator may include the following:
- Alcohol or drug abuse
- Use of prescription drugs that may dull the sensorium, or hinder decision-making during the period of participation in the study such has opioids or short-acting benzodiazepines
- Coronary artery disease that is not stable with medical management, including unstable angina, angina that prevents moderate exercise (e.g., climbing a flight of stairs) despite medical management; or within the last 12 months before screening: a history of myocardial infarction, percutaneous coronary intervention, enzymatic lysis of a presumed coronary occlusion, or coronary artery bypass grafting
- Congestive heart failure with New York Heart Association (NYHA) Functional Classification III or IV
- History of TIA or stroke in the last 12 months
- Severe liver disease such as end-stage cirrhosis
- Renal failure requiring dialysis or known eGFR <30
- Untreated or inadequately treated mental illness
- History of untreated or inadequately treated eating disorder within the last 2 years, such as anorexia, bulimia, or diabulimia or omission of insulin to manipulate weight
- History of intentional, inappropriate administration of insulin leading to severe hypoglycemia requiring treatment
-
Employed by, or having immediate family members employed by Beta Bionics, or being directly involved in conducting the clinical trial, or having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:UC Group
Participants randomized to the Usual Care (UC) group will use their existing insulin delivery method in conjunction with a study CGM during the first 13-week of the study (RCT phase). The UC group will then initiate use of the BP System for the remaining 13 weeks of the study (Extension Phase). |
The iLet Bionic Pancreas System (BP) consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls insulin delivery based on glucose values obtained by communicating with a CGM sensor. Usual Care consists in the participant existing insulin therapy (prior to enrollment) in conjunction with a study CGM. Existing insulin therapies are defined as multiple daily injections of insulin (MDI) or use of an insulin pump. |
|
実験的:BP Group
Participants randomized to the intervention group will use the BP group using the iLet Bionic Pancreas System (BP) and continuous glucose monitoring (CGM) during the first 13-week of the study (RCT phase). After the RCT phase, participants will continue in a 13-week Extension Phase in which the BP group will continue to use the BP system. |
The iLet Bionic Pancreas System (BP) consists of an integrated infusion pump, touchscreen display, Bluetooth radio, and insulin dosing algorithms, that automatically controls insulin delivery based on glucose values obtained by communicating with a CGM sensor. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
CGM-measured Time In Target Range of 70-180 mg/dL (TIR)
時間枠:13 weeks
|
CGM-measured time in target range of 70-180 mg/dL (TIR) |
13 weeks
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
CGM-measured Time In Range <54 mg/dL
時間枠:13 weeks
|
CGM-measured time in range <54 mg/dL |
13 weeks
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
CGM-measured Mean Glucose
時間枠:13 weeks
|
Average glucose value measured by CGM |
13 weeks
|
|
CGM-measured Time In Range >180 mg/dL
時間枠:13 weeks
|
CGM-measured time in range >180 mg/dL |
13 weeks
|
|
CGM-measured Time In Range >250 mg/dL
時間枠:13 weeks
|
CGM-measured time in range >250 mg/dL |
13 weeks
|
|
HbA1c At 13 Weeks
時間枠:13 weeks
|
HbA1c at 13 weeks |
13 weeks
|
|
Glucose Variability Measured With the Standard Deviation (SD)
時間枠:13 weeks
|
Glucose variability measured with the standard deviation (SD) |
13 weeks
|
|
CGM-measured Time In Range <70 mg/dL
時間枠:13 weeks
|
CGM-measured time in range <70 mg/dL |
13 weeks
|
|
Glucose Variability With the Coefficient of Variation (CV)
時間枠:13 weeks
|
Glucose variability with the coefficient of variation (CV) |
13 weeks
|
|
HbA1c <7.0% At 13 Weeks
時間枠:13 weeks
|
HbA1c <7.0% at 13 weeks |
13 weeks
|
|
HbA1c <7.0% At 13 Weeks In Participants With Baseline HbA1c >7.5%
時間枠:13 weeks
|
HbA1c <7.0% at 13 weeks in participants with baseline HbA1c >7.5% |
13 weeks
|
|
HbA1c <8.0% At 13 Weeks
時間枠:13 weeks
|
HbA1c <8.0% at 13 weeks |
13 weeks
|
|
HbA1c Improvement From Baseline To 13 Weeks >0.5%
時間枠:13 weeks
|
HbA1c improvement from baseline to 13 weeks >0.5% |
13 weeks
|
|
HbA1c Improvement From Baseline To 13 Weeks >1.0%
時間枠:13 weeks
|
HbA1c improvement from baseline to 13 weeks >1.0% |
13 weeks
|
|
HbA1c Improvement From Baseline To 13 Weeks >1.0% Or HbA1c <7.0% At 13 Weeks
時間枠:13 weeks
|
HbA1c improvement from baseline to 13 weeks >1.0% or HbA1c <7.0% at 13 weeks |
13 weeks
|
|
CGM-measured Time In Tight Range (TITR) 70-140 mg/dL
時間枠:13 weeks
|
CGM-measured time in tight range (TITR) 70-140 mg/dL |
13 weeks
|
|
CGM-measured Area Over the Curve (70 mg/dL)
時間枠:13 weeks
|
CGM-measured area over the curve (70 mg/dL) |
13 weeks
|
|
CGM-measured Low Sensor Glucose Events
時間枠:13 weeks
|
CGM-measured low sensor glucose events |
13 weeks
|
|
CGM-measured Prolonged High Sensor Glucose Events
時間枠:13 weeks
|
CGM-measured prolonged high sensor glucose events |
13 weeks
|
|
CGM-measured Time >300 mg/dL
時間枠:13 weeks
|
CGM-measured time >300 mg/dL |
13 weeks
|
|
CGM-measured Area Under the Curve (180 mg/dL)
時間枠:13 weeks
|
CGM-measured area under the curve (180 mg/dL) |
13 weeks
|
|
CGM-measured TIR >70%
時間枠:13 weeks
|
CGM-measured TIR >70% |
13 weeks
|
|
CGM-measured TIR Improvement From Baseline To 13 Weeks ≥5%
時間枠:13 weeks
|
CGM-measured TIR improvement from baseline to 13 weeks ≥5% |
13 weeks
|
|
CGM-measured TIR Improvement From Baseline To 13 Weeks ≥10%
時間枠:13 weeks
|
CGM-measured TIR improvement from baseline to 13 weeks ≥10% |
13 weeks
|
|
CGM-measured Time <70 mg/dL <4%
時間枠:13 weeks
|
CGM-measured time <70 mg/dL <4% |
13 weeks
|
|
CGM-measured Time <54 mg/dL <1%
時間枠:13 weeks
|
CGM-measured time <54 mg/dL <1% |
13 weeks
|
|
CGM-measured TIR >70% and Time <54 mg/dL <1%
時間枠:13 weeks
|
CGM-measured TIR >70% and time <54 mg/dL <1% |
13 weeks
|
|
CGM-measured Improvement In TIR By >10% Without An Increase In Time <54 mg/dL By >0.5%
時間枠:13 weeks
|
CGM-measured improvement in TIR by >10% without an increase in time <54 mg/dL by >0.5% |
13 weeks
|
|
Type 1 Diabetes Distress Scale (T1-DDS)
時間枠:Screening, 13 weeks
|
The T1-DDS is to evaluate diabetes-related emotional distress in type 1 diabetic patients. The scale consists of 17 items, contains 4 domains (emotional burden subscale, physician-related subscale, regimen-related distress subscale, and diabetes-related interpersonal distress). Each item is rated on a 6-point Likert scale from 1 (no problem) to 6 (serious problem). Patients with higher scores are considered with more distress |
Screening, 13 weeks
|
|
Problem Areas In Diabetes - Teens (PAID-T) and Parents of Teens (P-PAID-T)
時間枠:Screening, 13 weeks
|
The PAID-T and P-PAID-T questionnaires consist of 26 items that are scored on a 6-point Likert scale from 1-2 (not a problem) to 5-6 (serious problem). The derived total score (26 questions) ranges between 26 and 156, where high scores represent a higher burden |
Screening, 13 weeks
|
|
Hypoglycemia Confidence Scale (≥18)
時間枠:Screening, 13 weeks
|
A person-reported outcome measure (PROM) that examines the degree to which people with diabetes feel able, secure, and comfortable regarding their ability to stay safe from hypoglycemic-related problems (9-item scale with 4 choices that range from 1 (Not Confident At All) to 4 (Very Confident)). The total score can range from 1 to 4, with a higher score indicating a better outcome |
Screening, 13 weeks
|
|
INSPIRE Survey (Insulin Delivery Systems: Perceptions, Ideas, Reflections, and Expectations)
時間枠:Screening, 13 weeks
|
INSPIRE 5-point Likert scale from strongly agree to strongly disagree, along with an N/A option |
Screening, 13 weeks
|
|
Fear of Hypoglycemia Survey (HFS-II) - Total Score, 2 Subscales and 4 Factor Scores
時間枠:Screening, 13 weeks
|
Fear of Hypoglycemia Survey (HFS-II) - total score, 2 subscales and 4 factor scores: Behavior (avoidance, maintain high BG), Worry (helplessness, social consequences) |
Screening, 13 weeks
|
|
The EuroQol 5 Dimension 5 Level (EQ-5D-5L)
時間枠:Screening, 13 weeks
|
The EQ-5D-5L is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical appraisal. The EQ-5D evaluates 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) using a 5-level severity scale from 1 (no problems) to 5 (extreme problems), and is converted to a single summary index by applying a formula that essentially attaches weight to each of the levels in each dimension. The visual analogue score (VAS) evaluates the health condition assessed by patients to producae a quantitive measure of health outcome that reflects the patient's own judgement on a range from "the worst health you can imagine" to "the best health you can imagine" |
Screening, 13 weeks
|
|
World Health Organization Well-being Index (WHO-5)
時間枠:Screening, 13 weeks
|
WHO-5 is a 5-item questionnaire of the World Health Organization that measures health related quality of life. Each item is scored on a scale of 0 (at no time) to 5 (all the time). Higher scores indicate greater well-being |
Screening, 13 weeks
|
|
Perceived Benefits and Burdens of AID Systems
時間枠:Screening, 13 weeks
|
A 35-item survey that assesses user expectations of a hybrid closed loop AID system using a 5-point Likert scale from "strongly disagree" to "strongly agree" |
Screening, 13 weeks
|
|
Total Daily Insulin (Units/kg)
時間枠:13 weeks
|
Total daily insulin (Units/kg) |
13 weeks
|
|
Percentage of Total Insulin Delivered Via Basal
時間枠:13 weeks
|
Percentage of total insulin delivered via basal |
13 weeks
|
|
Percentage of Total Insulin Delivered Via Bolus
時間枠:13 weeks
|
Percentage of total insulin delivered via bolus |
13 weeks
|
|
Weight
時間枠:13 weeks
|
Weight |
13 weeks
|
|
Body Mass Index (BMI)
時間枠:13 weeks
|
Body Mass Index (BMI) |
13 weeks
|
|
Number of Severe Hypoglycemia (SH) Events and SH Event Rate Per 100 person-years
時間枠:13 weeks
|
Number of Severe Hypoglycemia (SH) events and SH event rate per 100 person-years |
13 weeks
|
|
Number of Diabetes Ketoacidosis (DKA) Events and DKA Event Rate Per 100 person-years
時間枠:13 weeks
|
Number of Diabetes Ketoacidosis (DKA) events and DKA event rate per 100 person-years |
13 weeks
|
|
Number of Other Serious Adverse Events (SAEs other than SH events and DKA events)
時間枠:13 weeks
|
Number of Other Serious Adverse Events (SAEs other than SH events and DKA events) |
13 weeks
|
|
Number of Unanticipated Adverse Device Effects (UADE)
時間枠:13 weeks
|
Number of Unanticipated Adverse Device Effects (UADE) |
13 weeks
|
|
Number of Infusion Set Failures
時間枠:13 weeks
|
Number of infusion set failures |
13 weeks
|
|
Other Device Malfunctions/Device Issues
時間枠:13 weeks
|
Number of other malfunctions/issues related to the study device |
13 weeks
|
協力者と研究者
捜査官
- スタディチェア:Melissa Putman, MD、Massachusetts General Hospital
- スタディディレクター:Judy Sibayan, MPH、Jaeb Center for Health Research
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- BPCFRD
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。